Sen-Jam Is Building a Broad-Spectrum Anti-Inflammatory Platform for Longer, Healthier Lives
StartUp Health community members Jim Iversen and Jackie Iversen, RPh, MS, the co-founders of Sen-Jam Pharmaceutical, are advancing a platform of five de-risked, Phase 2–stage assets to regulate systemic inflammation at its root, extend healthspan, and open a trillion-dollar longevity category.
We recently caught up with StartUp Health community members Jim Iversen, CEO & Co-founder, and Jackie Iversen, RPh, MS, Chief Clinical Officer & Co-founder of Sen-Jam, for a Health Moonshot Update to learn why they focus on moving care upstream. Jackie began her career as a hospital pharmacist, asked to improve outcomes while costs climbed. “We spend so much of our pharmaceutical spend and our healthcare dollars on sick care – treating people after damage has already taken hold,” she explained. “My mission became: how do we prevent that damage from occurring in the first place?”
That mission has shaped Sen-Jam’s trajectory. Instead of treating disease late and narrowly, the company aims to regulate systemic inflammation safely and broadly, so people can stay healthier, longer. Their one-liner captures it: transforming systemic inflammation, the silent killer, into longer, healthier lives.
This is not a single-asset biotech. Sen-Jam has a robust pipeline of 11 unique drugs, with five lead, IP-protected assets that are de-risked and progressing through Phase 2 or beyond. “We’ve built a platform, not a single drug story,” Jim emphasized. “Five lead assets, each IP-protected, and each with multiple shots on goal.”
The company’s approach combines well-characterized components with an immuno-regulatory, dual mechanism of action that touches five and six inflammatory pathways, which is a leap ahead of today’s single inflammatory mediator mechanisms.
By using the FDA 505(b)(2) path, they seek to accelerate timelines, reduce cost, and lower development risk. More than 60 patents are granted or pending worldwide, with patent life extending into the 2040s.
From Sickcare to Healthspan
Jim frames the macro problem simply. “Sixty to seventy percent of deaths are inflammatory related,” he said. “At the end of life, there’s this crisis of inflammation that has been building up for decades.” Americans live, on average, more than a decade with significant disease or disability near the end of life. Sen-Jam’s answer is a pharmacologic platform designed for long-term use without immunosuppression, so people can begin prevention earlier and stay on therapy safely.
The strategy starts with acute indications, where approvals are faster and signal clarity is high, then extends into chronic, low-grade “inflammaging” that accelerates age-related disease and the decline of immune responsiveness in aging known as “immunosenescence.” Tackle both, and you move beyond “anti-inflammatory” toward true healthspan extension.
Evidence and Momentum
Sen-Jam recently completed a Phase 2 study with Duke University in patients with active COVID. Although cases were mild, the trial delivered what the team most needed at this stage: an exceptional side-effect profile that supports long-term administration. “The side effect profile was key,” Jackie noted. “If you want to use these drugs long term, you need the best safety profile ever – and that’s exactly what we saw.”
Five lead assets now define the near-term arc:
SJP-001 targets alcohol-induced inflammation. A Phase 2 prevention study is underway in Canada, with data expected by year-end. The goal is not just to ease next-day symptoms. “People think hangovers are dehydration,” Jackie explained. “We’re going to prove it’s inflammation – and we’ll show it in the biomarkers.” The hangover market is estimated to exceed $6 billion by 2032, and Sen-Jam aims to lead it.
SJP-002C sits at the intersection of obesity, metabolic disease, and respiratory infections. Jim pointed out that while GLP-1 therapies like Ozempic have become household names, “we’re now seeing the side effects, the weight regain, and the muscle-to-fat imbalances.” Sen-Jam believes SJP-002C can complement GLP-1s by reducing neuroinflammation that drives hunger and set-point defense, supporting preferential fat loss, and helping maintain weight reduction after patients step down from injectables.
SJP-002 for the common cold has received a core patent, validating the mechanism across upper respiratory inflammation.
SJP-005 addresses opioid withdrawal, with multiple patents granted and pending. Sen-Jam is co-sponsored by the National Institute on Drug Abuse for animal studies in methamphetamine use disorder, a key validation for the hypothesis that neuroinflammation underlies a spectrum of addictive behaviors.
SJP-I00 is geared for hospital critical-care rescue, where a cytokine storm turns inflammation into an organ-threatening emergency.
Underpinning the portfolio is broad, durable IP. Sen-Jam holds more than 60 patents granted or pending worldwide, with exclusivity stretching into the 2040s. Chemistry, manufacturing, and controls are anchored by KVK-Tech in Pennsylvania, which is producing FDA-ready batches across several assets. On the advisory front, the team works with Alexander Wissner-Gross, a renowned physicist and AI expert, to guide prioritization and modeling.
Why This Matters
Sen-Jam’s platform is designed for more than acute symptom relief. By addressing systemic inflammation broadly and safely, their therapies open the door to preventing disease at its root and extending healthy years of life. The company’s IP-protected programs, Phase 2-ready assets, and broad applicability create multiple entry points for collaboration. “We’re building a new category of anti-inflammatories,” Jackie said. “The broadest spectrum, the safest profile, and suitable for chronic use. Nobody’s done this before.”
What’s Next
Near term, Sen-Jam is focused on fully funding and completing the Phase 2 trial for SJP-001 in Canada. In parallel, the team is advancing outreach around SJP-002C in the GLP-1 and metabolic arena, supported by a long patent runway and a mechanism that suggests real synergy. Across the company’s portfolio, the goal is to drive all five lead assets through Phase 2 over the next two years, then extend into chronic indications as the regulatory path allows.
Jackie is also taking Sen-Jam’s story to some of the biggest stages in health innovation this fall. She has been invited as a keynote voice at the TEDx Longevity Conference in Boston in mid-October, where she’ll spotlight Sen-Jam’s breakthrough approach to inflammaging and healthspan. Earlier that month, she will address global biotech leaders at the 25th Annual Biotech in Europe Forum in Switzerland, bringing Sen-Jam’s vision for platform-based, systemic inflammation regulation to an international investor and pharma audience.
To help fuel this progress, Sen-Jam has opened access to its journey through WeFunder, alongside traditional venture channels. As members of the StartUp Health community, Jim and Jackie are sharing their milestones regularly and engaging with peers who are tackling longevity and healthspan from different angles. Jim has led a Masterclass on crowdfunding for fellow founders in the community, underscoring Sen-Jam’s dedication as a mentor helping others navigate the path to growth. It is a reminder of the power of community: when founders, partners, and leaders connect around bold health moonshots, extraordinary progress becomes possible.
“We’ve been on a really adventurous rocket ship,” Jim said with a smile. “And we’d like to share it with everyone.”
Connect with Sen-Jam Pharmaceutical via email
Join StartUp Health
An exclusive global community for the bold decision makers, thought leaders, funders, and innovators transforming the future of health
Network Plans for Everyone in the Ecosystem: If you're a decision maker, thought leader, funder, or industry stakeholder – this is where the global health ecosystem comes together to learn from experts, share insights, build relationships, explore partnerships, and shape what’s next in health. Join today, no application necessary.
Health Moonshot Plans for Startups & Scaleups: If you're a founder or CEO building a digital health, biotech, or life sciences company, our Health Moonshot Communities are designed for collaboration, coaching, and strategic growth at every stage. Our communities include: Alzheimer’s & Brain Health, Cardiometabolic & T1D, Food as Medicine, Mental & Behavorial Health, and more. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. Learn more and apply today.
Follow us on LinkedIn for daily updates on Health Moonshots.
Published: Sep 23, 2025
By Nicole Kinsey
